We are live on ! Find out more

Mangoceuticals

MGRX

Market cap $3.66M

0.1649 USD

-0.0201

10.86%

At close Updated Nov 13, 11:12 AM EST

1 day

-10.86%

5 days

-18.41%

1 month

-55.62%

3 months

-69.07%

6 months

-51.5%

Year to date

-80.68%

1 year

-86.14%

5 years

-99.73%

10 years

-99.73%

About: Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Healthcare Health Information Services

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform

Series D Preferred Stock to be offered at $10.00 per share through the issuance of tokens and issued natively on-chain, with T7X Equities serving as transfer agent; no common stock will be issued at closing DALLAS, TX, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”), a company focused on developing, marketing and selling health and wellness products through its telemedicine platforms under the MangoRx and PeachesRx brands, today announced a partnership with T7X, a compliance-first digital asset infrastructure company, to issue a new series of tokenized preferred stock natively on T7X's blockchain infrastructure. Upon issuance, Mangoceuticals expects to become the first Nasdaq-listed company to issue a security on the T7X platform.

Mangoceuticals Partners with T7X to Become the First Nasdaq-Listed Company to Offer Tokenized Preferred Stock on the T7X Platform

Nike, Synaptics And 3 Stocks To Watch Heading Into Friday

With U.S. stock futures trading higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:

Nike, Synaptics And 3 Stocks To Watch Heading Into Friday

Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

Subsidiary-Level Investment Provides Capital to Advance Commercialization of the Company's Antiviral Intellectual Property Portfolio with No Issuance of MGRX Common Stock

Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Mangoceuticals, Inc. (NASDAQ: MGRX) and Nuclea Energy Inc. Halper Sadeh encourages Mangoceuticals shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or [email protected] or [email protected]. The investigation concerns whether Mangoceuticals and its board of directors violated the federa.

MGRX Stock Alert: Halper Sadeh LLC is Investigating Whether Mangoceuticals, Inc. is Obtaining a Fair Price for its Shareholders

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

Nuclea Energy, Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

The acquisition of Moltex brings over a decade of advanced nuclear R&D, backed by more than C$96 million in private investment and public funding from Canada and the U.S. Department of Energy. Asset-led transaction to add intellectual property and development materials related principally to the SSR-W advanced reactor and WATSS spent nuclear fuel recycling technologies.

Mangoceuticals Inc.'s Merger Partner, Nuclea Energy, Inc., Enters into Definitive Agreement to Acquire Moltex Energy's Advanced Nuclear Technology Assets

Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter capacity Dallas, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that its merger partner, Nuclea Energy Inc. (“Nuclea”), an advanced nuclear technology company headquartered in Mississauga, Ontario, has signed a non-binding memorandum of understanding (the “MOU”) with New Mining Co. (“New Mining”), a Miami-headquartered provider of high-density digital infrastructure and computing hosting services, to evaluate the technical and structural feasibility of deploying Nuclea's modular reactor technology to serve New Mining's behind-the-meter power needs. “High-density computing infrastructure is precisely the kind of behind-the-meter application our technology is engineered for, and this collaboration enables us to evaluate that fit rigorously alongside a partner who understands large-scale, mission-critical power demand.

Mangoceuticals' Merger Partner, Nuclea Energy Inc., Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

The MOU will assess the technical feasibility of integrating Nuclea's modular reactor technology into New Mining's data center operations, with a phased evaluation path toward a cumulative 100 MWe of behind-the-meter capacity Mississauga, Ontario--(Newsfile Corp. - August 6, 2026) - Nuclea Energy Inc. ("Nuclea"), an advanced nuclear technology company headquartered in Mississauga, Ontario, today announced that it has signed a non-binding memorandum of understanding (the "MOU") with New Mining Co. ("New Mining"), a Miami-headquartered provider of high-density digital infrastructure and computing hosting services, to evaluate the technical and structural feasibility of deploying Nuclea's modular reactor technology to serve New Mining's behind-the-meter power needs. "High-density computing infrastructure is precisely the kind of behind-the-meter application our technology is engineered for, and this collaboration enables us to evaluate that fit rigorously alongside a partner who understands large-scale, mission-critical power demand.

Nuclea Energy Signs MOU with New Mining Co. to Advance Behind-the-Meter Modular Reactor Deployment for High-Density Computing Infrastructure

Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab and engagement with the U.S. Department of Energy and Nuclear Regulatory Commission to advance the Morpheus microreactor toward demonstration and deployment Dallas, Texas, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) today announced that its merger partner's wholly owned subsidiary, Nuclea Energy USA Inc. (“Nuclea USA”), has signed a memorandum of understanding (the “MOU”) with the State of Utah Office of Energy Development (“OED”) to explore the siting of a nuclear test reactor at the Utah San Rafael Energy Lab (“USREL”) to advance the deployment of the Morpheus microreactor. The MOU marks an important step in advancing research, development and commercial deployment of Nuclea's micro-modular reactor.

Mangoceuticals' Merger Partner, Nuclea Energy (“Nuclea”), Executes MOU with Utah Office of Energy Development

Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development

The MOU supports exploration of a nuclear test reactor site at the Utah San Rafael Energy Lab to advance the Morpheus microreactor toward demonstration and deployment Salt Lake City, Utah--(Newsfile Corp. - August 5, 2026) - Nuclea Energy USA Inc. ("Nuclea USA"), a wholly owned subsidiary of Nuclea Energy Inc. ("Nuclea"), an advanced nuclear technology developer, is pleased to publicly announce the signing of a memorandum of understanding (MOU) on June 2, 2026 with the State of Utah Office of Energy Development ("OED") to explore the siting of a nuclear test reactor at the Utah San Rafael Energy Lab ("USREL") to advance the deployment of Nuclea's Morpheus Micro Reactor. The MOU marks an important step in advancing research, development and commercial deployment of Nuclea's micro modular reactor.

Nuclea Energy USA Inc. Announces MOU with Utah Office of Energy Development

See News Rankings

Price charts implemented using Lightweight Charts™